Removal of Toxins and Pathogens Using Human Monoclonal and Bispecific Antibodies

Project Summary

The threat of biological and chemical weapons necessitates the development of highly effective methods which provide both prophylaxis and therapies for specific groups, such as first responders or the military, who are at risk due to potential attack.

This project brought together expertise from the academic, government, and private sectors to develop a novel product to protect individuals, including first responders, from anthrax infection. A human monoclonal antibody was developed that is directed against the anthrax protective antigen. Addition of this antibody neutralizes anthrax toxin activity in vitro. The antibody protects animals infected with high levels of B. anthracis spores and in some cases it reversed symptoms after the onset of disease. The antibody has continued to be developed through a joint venture between Medarex and PharmAthene. It has recently been successfully tested in Phase I clinical trials. This antibody is generally regarded as the best anti-anthrax product available.

• Project Leads: Ronald Taylor, Michael Fanger